The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Official Title: Slow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront Therapy
Study ID: NCT04754945
Brief Summary: This phase I trial studies the side effects of isatuximab and to see how well it works in treating patients with high risk immunoglobulin light chain amyloidosis (AL amyloidosis). Isatuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.
Detailed Description: PRIMARY OBJECTIVES: 1. Test the safety and feasibility of isatuximab-based drug treatment. 2. Evaluate the preliminary efficacy of a slow-go approach in high risk AL amyloid patients. STUDY TREATMENT Each patient starts by receiving increasing intensity of treatment for AL Amyloidosis up to maximum tolerance, and then maintenance Isatuximab thereafter for a specified period. All patients will receive Isatuximab (weekly x 4 then every other week) plus dexamethasone 4 mg PO/IV days weekly. If tolerating Isatuximab/Dex4 (earliest time to escalate C1D15), add Velcade to 1 mg/m2 SQ weekly. If tolerating Isa/Vel1.0/Dex4 (earliest time to escalate C2D1), increase dexamethasone to 12 mg weekly. If tolerating Isa/Velcade1.0/Dex12 (earliest time to escalate C3D1), increase Velcade to 1.3 mg/m2 SQ. If tolerating Isa/Velcade1.3/Dex12 (earliest time to escalate C4D1), add cyclophosphamide 300 mg IV weekly. If tolerating Isa/Velcade1.3/Cy300/Dex12 (earliest time to escalate C5D1), increase cyclophosphamide to 400 mg IV weekly. If tolerating Isa/Velcade1.3/Cy400/Dex12 (earliest time to escalate C6D1), increase cyclophosphamide to 500 mg IV weekly. Tolerance determined by the patient not reaching an escalation limiting toxicity AND patient approval to dose escalate. Patients then receive dexamethasone and isatuximab as maintenance treatment twice per month for 12 months in the absence of disease progression or unacceptable toxicity.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of California, Orange, California, United States
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Emory University Hospital Midtown, Atlanta, Georgia, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Columbia University, New York, New York, United States
UT Southwestern, Dallas, Texas, United States
Name: Craig C Hofmeister, MD, MPH
Affiliation: Emory University
Role: PRINCIPAL_INVESTIGATOR